Brokerages Set Envista Holdings Co. (NYSE:NVST) PT at $20.21

Shares of Envista Holdings Co. (NYSE:NVST) have been assigned a consensus rating of “Hold” from the fourteen research firms that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $20.21.

NVST has been the topic of a number of research analyst reports. Mizuho initiated coverage on Envista in a research report on Wednesday, December 4th. They set an “underperform” rating and a $20.00 price target on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Envista in a research report on Thursday, February 6th. Piper Sandler raised their price target on Envista from $17.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, February 3rd. Robert W. Baird raised their price target on Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research report on Thursday, October 31st. Finally, Wells Fargo & Company raised their price target on Envista from $20.00 to $21.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 6th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Brickwood Asset Management LLP bought a new position in Envista in the fourth quarter valued at approximately $40,037,000. Vise Technologies Inc. grew its stake in Envista by 14.7% in the fourth quarter. Vise Technologies Inc. now owns 16,016 shares of the company’s stock valued at $309,000 after purchasing an additional 2,056 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Envista by 15.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 492,736 shares of the company’s stock valued at $9,505,000 after purchasing an additional 67,234 shares in the last quarter. Two Sigma Advisers LP grew its stake in Envista by 66.6% in the fourth quarter. Two Sigma Advisers LP now owns 47,800 shares of the company’s stock valued at $922,000 after purchasing an additional 19,100 shares in the last quarter. Finally, Tidal Investments LLC boosted its stake in shares of Envista by 53.9% during the 4th quarter. Tidal Investments LLC now owns 31,307 shares of the company’s stock worth $604,000 after acquiring an additional 10,958 shares during the period.

Envista Price Performance

Envista stock opened at $20.91 on Tuesday. Envista has a 12-month low of $15.15 and a 12-month high of $23.06. The business’s 50-day simple moving average is $20.11 and its 200 day simple moving average is $19.52. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The stock has a market cap of $3.60 billion, a price-to-earnings ratio of -3.22, a P/E/G ratio of 1.27 and a beta of 1.34.

Envista (NYSE:NVST) last released its earnings results on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. As a group, research analysts anticipate that Envista will post 1 earnings per share for the current year.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.